Analysts Set Merus (NASDAQ:MRUS) Target Price at $56.33

Merus (NASDAQ:MRUS) has been assigned an average recommendation of “Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat reports. Eleven investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $56.33.

Several research analysts have commented on the stock. HC Wainwright raised their price target on shares of Merus from $48.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 29th. William Blair restated an “outperform” rating on shares of Merus in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price target on shares of Merus in a research report on Thursday, April 11th. Truist Financial began coverage on shares of Merus in a research report on Thursday, March 28th. They issued a “buy” rating and a $69.00 price objective on the stock. Finally, Stifel Nicolaus lifted their target price on shares of Merus from $40.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th.

Merus Stock Performance

Shares of MRUS opened at $41.97 on Monday. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of -13.81 and a beta of 1.10. Merus has a 52-week low of $18.21 and a 52-week high of $52.03. The stock’s 50-day simple moving average is $45.03 and its 200 day simple moving average is $33.52.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). The firm had revenue of $8.94 million during the quarter, compared to analysts’ expectations of $10.43 million. Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. On average, research analysts forecast that Merus will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC grew its stake in shares of Merus by 37.7% during the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 343 shares during the last quarter. BluePath Capital Management LLC bought a new position in Merus during the 3rd quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. grew its position in Merus by 142.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 867 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Merus in the 1st quarter worth approximately $72,000. Finally, Tower Research Capital LLC TRC lifted its position in Merus by 64.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 828 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.